Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus granules twice-daily for intractable vascular malformations
jRCTs031200055Active, not recruiting
- Sponsor
- National Center for Global Health and Medicine
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in vascular malformation, lymphangioma, lymphangiomatosis (GLA) and 1 more, sponsored by National Center for Global Health and Medicine. Primary endpoint: Target lesion response rate at 24 weeks. Started Sep 2020; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
vascular malformationlymphangiomalymphangiomatosis (GLA)Gorham-Stout syndrome (GSS)
Beyond the preview
Go deeper on jRCTs031200055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200055.